Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient needs through science to improve their lives. Our noble purpose guides our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and pioneering medical dermatology products to bring our innovative solutions to patients in need.
Year founded1943
Served areaWorldwide
Headcount1,765
HeadquartersRonda General Mitre, 151, 8022 Barcelona – Spain
Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Assets | N/A | 2,291,114,000.00 | 2,141,744,000.00 | 2,147,691,000.00 |
Noncurrent Assets | N/A | 1,801,364,000.00 | 1,642,470,000.00 | 1,594,973,000.00 |
Property Plant And Equipment | N/A | 113,548,000.00 | 117,413,000.00 | 124,051,000.00 |
Goodwill | N/A | 315,966,000.00 | 315,966,000.00 | 315,966,000.00 |
Intangible Assets Other Than Goodwill | N/A | 1,009,536,000.00 | 916,056,000.00 | 898,677,000.00 |
Deferred Tax Assets | N/A | 256,476,000.00 | 192,500,000.00 | 182,971,000.00 |
Other Noncurrent Financial Assets | N/A | N/A | 80,502,000.00 | 34,655,000.00 |
Current Assets | N/A | 489,750,000.00 | 499,274,000.00 | 552,718,000.00 |
Inventories | N/A | 130,151,000.00 | 118,632,000.00 | 130,095,000.00 |
Trade And Other Current Receivables | N/A | 111,295,000.00 | 127,671,000.00 | 138,261,000.00 |
Current Tax Assets Current | N/A | N/A | 34,054,000.00 | 20,817,000.00 |
Other Current Financial Assets | N/A | 6,025,000.00 | 899,000.00 | 443,000.00 |
Other Current Nonfinancial Assets | N/A | 9,991,000.00 | 11,531,000.00 | 14,722,000.00 |
Cash and cash equivalents | 117,293,000.00 | 165,667,000.00 | 207,386,000.00 | 248,823,000.00 |
Equity And Liabilities | N/A | 2,291,114,000.00 | 2,141,744,000.00 | 2,147,691,000.00 |
Equity | 1,280,186,000.00 | 1,302,966,000.00 | 1,286,039,000.00 | 1,318,715,000.00 |
Issued Capital | N/A | 21,374,000.00 | 21,573,000.00 | 21,782,000.00 |
Share Premium | N/A | 273,889,000.00 | 295,785,000.00 | 317,315,000.00 |
Statutory Reserve | N/A | 4,189,000.00 | 4,275,000.00 | 4,275,000.00 |
Noncurrent Liabilities | N/A | 513,589,000.00 | 574,712,000.00 | 554,363,000.00 |
Noncurrent Provisions For Employee Benefits | N/A | 85,641,000.00 | 77,883,000.00 | 54,046,000.00 |
Other Longterm Provisions | N/A | 35,899,000.00 | 24,505,000.00 | 20,746,000.00 |
Deferred Tax Liabilities | N/A | 117,382,000.00 | 75,852,000.00 | 77,254,000.00 |
Other Noncurrent Financial Liabilities | N/A | 224,345,000.00 | 359,692,000.00 | 350,758,000.00 |
Other Noncurrent Nonfinancial Liabilities | N/A | 19,434,000.00 | 22,618,000.00 | 17,624,000.00 |
Current Liabilities | N/A | 474,559,000.00 | 280,993,000.00 | 274,613,000.00 |
Trade And Other Current Payables | N/A | 162,143,000.00 | 177,800,000.00 | 184,287,000.00 |
Current Tax Liabilities Current | N/A | 21,460,000.00 | 19,471,000.00 | 26,643,000.00 |
Other Current Financial Liabilities | N/A | 248,300,000.00 | 12,314,000.00 | 12,402,000.00 |
Other Current Nonfinancial Liabilities | N/A | 36,394,000.00 | 65,130,000.00 | 46,181,000.00 |
Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
---|---|---|---|
Revenue | 807,427,000.00 | 827,195,000.00 | 863,248,000.00 |
Other Income | 7,062,000.00 | 9,305,000.00 | 15,263,000.00 |
Other Work Performed By Entity And Capitalised | 4,941,000.00 | 8,932,000.00 | 7,539,000.00 |
Raw Materials And Consumables Used | 177,442,000.00 | 181,752,000.00 | 189,324,000.00 |
Other Employee Expense | 177,004,000.00 | 188,420,000.00 | 201,660,000.00 |
Depreciation And Amortisation Expense | 123,085,000.00 | 119,937,000.00 | 120,636,000.00 |
Other Expense By Nature | 229,005,000.00 | 247,584,000.00 | 307,788,000.00 |
Profit Loss From Operating Activities | 92,298,000.00 | 5,752,000.00 | 46,866,000.00 |
Finance Income | 1,579,000.00 | 493,000.00 | 637,000.00 |
Finance Costs | 18,003,000.00 | 20,600,000.00 | 12,785,000.00 |
Profit Loss Before Tax | 79,238,000.00 | -9,085,000.00 | 31,027,000.00 |
Income Tax Expense Continuing Operations | 4,958,000.00 | 31,774,000.00 | 26,746,000.00 |
Profit (loss) | 74,280,000.00 | -40,859,000.00 | 4,281,000.00 |
Profit Loss Attributable To Owners Of Parent | 74,280,000.00 | -40,859,000.00 | 4,281,000.00 |
Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
---|---|---|---|---|
Profit (loss) | N/A | 74,280,000.00 | -40,859,000.00 | 4,281,000.00 |
Adjustments For Finance Costs | N/A | 18,003,000.00 | 20,600,000.00 | 12,785,000.00 |
Adjustments For Decrease Increase In Inventories | N/A | 25,329,000.00 | -13,338,000.00 | 10,695,000.00 |
Adjustments For Depreciation And Amortisation Expense | N/A | 123,085,000.00 | 119,937,000.00 | 120,636,000.00 |
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | N/A | -16,197,000.00 | -90,844,000.00 | 0.00 |
Adjustments For Provisions | N/A | 3,195,000.00 | -3,357,000.00 | 2,285,000.00 |
Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | -742,000.00 | 2,044,000.00 | 1,984,000.00 |
Adjustments For Fair Value Gains Losses | N/A | 4,106,000.00 | 3,218,000.00 | -5,675,000.00 |
Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | -649,000.00 | -13,871,000.00 | -4,863,000.00 |
Cash Flows From Used In Operating Activities | N/A | 112,757,000.00 | 233,852,000.00 | 155,102,000.00 |
Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 11,891,000.00 | 18,814,000.00 | 23,007,000.00 |
Purchase Of Intangible Assets Classified As Investing Activities | N/A | 64,635,000.00 | 52,338,000.00 | 93,473,000.00 |
Interest Received Classified As Investing Activities | N/A | 1,082,000.00 | 28,000.00 | 170,000.00 |
Cash Flows From Used In Investing Activities | N/A | -23,517,000.00 | -57,255,000.00 | -68,543,000.00 |
Payments To Acquire Or Redeem Entitys Shares | N/A | 82,000.00 | -596,000.00 | -46,000.00 |
Repayments Of Borrowings Classified As Financing Activities | N/A | 16,882,000.00 | 154,488,000.00 | 10,000,000.00 |
Payments Of Lease Liabilities Classified As Financing Activities | N/A | 8,289,000.00 | 7,772,000.00 | 7,200,000.00 |
Dividends Paid Classified As Financing Activities | N/A | 2,129,000.00 | 11,746,000.00 | 12,419,000.00 |
Interest Paid Classified As Financing Activities | N/A | 6,536,000.00 | 6,130,000.00 | 9,899,000.00 |
Other Inflows Outflows Of Cash Classified As Financing Activities | N/A | -6,948,000.00 | 251,000.00 | -5,650,000.00 |
Cash Flows From Used In Financing Activities | N/A | -40,866,000.00 | -134,878,000.00 | -45,122,000.00 |
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 48,374,000.00 | 41,719,000.00 | 41,437,000.00 |
Cash and cash equivalents | 117,293,000.00 | 165,667,000.00 | 207,386,000.00 | 248,823,000.00 |
Please note that some sums might not add up.
ES0157097017
LEI95980020140005007996
SectorHealth Care Equipment & Services
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.